jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2012-4-4-5-12jofin-126Research ArticleОбзорыReviewМАЛЫЕ ИНТЕРФЕРИРУЮЩИЕ РНК – НОВОЕ НАПРАВЛЕНИЕ ПРОТИВОВИРУСНОЙ ТЕРАПИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОЙ ВИРУСНОЙ ИНФЕКЦИИThe promise and progress of RNA-interference-based antiviral therapy for respiratory syncytial virus.ВысочинскаяВ. В.VysochinskayаV. V.

клинический ординатор отделения экспериментальной терапии хронических вирусных гепатитов НИИ гриппа; тел: 8-921-591-72-47

veravv2509@gmail.comЭсауленкоЕ. В.EsaulenkoE. V.

заведующая кафедрой инфекционных болезней взрослых и эпидемиологии Санкт-Петербургской государственной педиатрической медицинской академии, д.м.н., профессор; тел./факс: 8(812)499-48-16

esaulenko@influenza.spb.ruБогдановА. А.BogdanovA. A.

старший научный сотрудник лаборатории нанобиотехнологий Санкт-Петербургского академического университета – научно-образовательного центра нанотехнологий РАН; тел: +7-911-228-80-00

aleks_aa@mail.ruГорабД. Н.GhorabD. N.

старший научный сотрудник лаборатории нанобиотехнологий Санкт-Петербургского академического университета – научно-образовательного центра нанотехнологий РАН; тел: +7-911-947-03-54

ddounya@hotmail.comКнязевН. А.КnyazevN. A.

младший научный сотрудник лаборатории нанобиотехнологий Санкт-Петербургского академического университета – научно-образовательного центра нанотехнологий РАН; тел: +7-921-321-64-49

nickolayknz@gmail.comДубинаМ. В.DubinaM. V.

заведующий лабораторией нанобиотехнологий Санкт-Петербургского академического университета – научно-образовательного центра нанотехнологий РАН, член-корреспондент РАН, д.м.н.; тел: +7-921-957-85-44

michael.dubina@gmail.comНаучно-исследовательский институт гриппа, Санкт-ПетербургРоссияScience Research Institute of Influenza, Saint-PetersburgRussian FederationСанкт-Петербургский академический университет – физико-технологический научно-образовательный центр нанотехнологий РАН, Санкт-ПетербургРоссияScience Research Institute of Influenza, Saint-PetersburgRussian FederationСанкт-Петербургский академический университет – физико-технологический научно-образовательный центр нанотехнологий РАН, Санкт-ПетербургРоссияSaint-Petersburg Academic University – Physics and Technology Research and Education Center of Nanotechnologies of Russian Academy of Sciences, Saint-PetersburgRussian Federation20121509201444512Copyright © Высочинская В.В., Эсауленко Е.В., Богданов А.А., Гораб Д.Н., Князев Н.А., Дубина М.В., 20142014Высочинская В.В., Эсауленко Е.В., Богданов А.А., Гораб Д.Н., Князев Н.А., Дубина М.В.Vysochinskayа V.V., Esaulenko E.V., Bogdanov A.A., Ghorab D.N., Кnyazev N.A., Dubina M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/126

Респираторно-синцитиальный вирус (РСВ) является ведущей причиной смертности среди новорожденных, детей раннего возраста и пожилых людей во всем мире. Подходы в отношении терапии РСВ-инфекции недостаточно эффективны и базируются на применении симптоматических методов лечения в связи с отсутствием эффективной противовирусной терапии. Современный прогресс в исследованиях механизма РНК-интерференции позволяет говорить о становлении нового класса противовирусных лекарственных средств в терапии РСВ-инфекции.

Respiratory syncytial virus (RSV) is a major cause of morbidity in infants, young children, and the elderly worldwide. Presently, there are no explicit recommendations for RSV treatment apart from supportive care. Recent progress in studies of the mechanism of RNA interference suggests the formation of a new class of antiviral drugs in the treatment of RSV infection and related respiratory diseases.

респираторный синцитиальный вирусмалые интерферирующие РНКРНК- интерференцияrespiratory syncytial virussmall interfering RNARNA interferenceReferencesVenkatesh, M.P. Prevention and treatment of respiratory syncytial virus infection in infants: an update / M.P. Venkatesh, L.E. Weisman // Expert. Rev. Vaccines. – 2006. – V. 5, № 2. – P. 261–268.Venkatesh, M.P. Prevention and treatment of respiratory syncytial virus infection in infants: an update / M.P. Venkatesh, L.E. Weisman // Expert. Rev. Vaccines. – 2006. – V. 5, № 2. – P. 261–268.Becker, Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy: a review / Y. Becker // Virus Genes. – 2006. – V. 33. – P. 235–252.Becker, Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy: a review / Y. Becker // Virus Genes. – 2006. – V. 33. – P. 235–252.Ebbert, J.O. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome /J.O. Ebbert, A.H. Limper // Respiration. – 2005. – V. 72, № 3. – P. 263–269.Ebbert, J.O. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome /J.O. Ebbert, A.H. Limper // Respiration. – 2005. – V. 72, № 3. – P. 263–269.Falsey, A.R. Respiratory syncytial virus infection in elderly and high-risk adults / A.R. Falsey [et al.] // N. Engl. J. Med. – 2005. – V. 352. – P. 1749–1759.Falsey, A.R. Respiratory syncytial virus infection in elderly and high-risk adults / A.R. Falsey [et al.] // N. Engl. J. Med. – 2005. – V. 352. – P. 1749–1759.Steele, R.W. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections / R.W. Steele // American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. – 1996. – V. 97, № 1. – P. 137–140.Steele, R.W. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections / R.W. Steele // American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. – 1996. – V. 97, № 1. – P. 137–140.Kim, H.W. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine /H.W. Kim, J.G. Canchola // Am. J. Epidemiol. – 1968. – V. 89. – P. 422–434.Kim, H.W. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine /H.W. Kim, J.G. Canchola // Am. J. Epidemiol. – 1968. – V. 89. – P. 422–434.The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants // Pediatrics. – 1998. – V. 102, № 3. – P. 531–537.The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants // Pediatrics. – 1998. – V. 102, № 3. – P. 531–537.Feltes, T.F. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease / T.F. Feltes [et al.] // J. Pediatr. – 2003. – V. 143, № 4. – P. 532–540.Feltes, T.F. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease / T.F. Feltes [et al.] // J. Pediatr. – 2003. – V. 143, № 4. – P. 532–540.Vogel, A.M. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants / A.M. Vogel [et al.] //J. Paediatr. Child. Health. – 2002. – V. 38, № 6. – P. 550– 554.Vogel, A.M. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants / A.M. Vogel [et al.] //J. Paediatr. Child. Health. – 2002. – V. 38, № 6. – P. 550– 554.Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections // Pediatrics. – 2003. – V. 112. – P. 1442–1446.Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections // Pediatrics. – 2003. – V. 112. – P. 1442–1446.Hampp, C. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications / C. Hampp [et al.] // Arch. Pediat. Adol. Med. – 2011. – V. 165, № 6. – P. 498– 505.Hampp, C. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications / C. Hampp [et al.] // Arch. Pediat. Adol. Med. – 2011. – V. 165, № 6. – P. 498– 505.Committee on Infectious Diseases. Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections // Pediatrics. – 2009. – V. 124. – P. 1694–1701.Committee on Infectious Diseases. Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections // Pediatrics. – 2009. – V. 124. – P. 1694–1701.Cohen, A.H. Phase IV study of the safety of synagis (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract] / A.H. Cohen [et al.] //American Thoracic Society. – 2005. –V. 2. – P. 178.Cohen, A.H. Phase IV study of the safety of synagis (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract] / A.H. Cohen [et al.] //American Thoracic Society. – 2005. –V. 2. – P. 178.Giebels, K. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis / K. Giebels [et al.] //Pediatr. Pulmonol. – 2008. – V. 43. – P. 169–174.Giebels, K. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis / K. Giebels [et al.] //Pediatr. Pulmonol. – 2008. – V. 43. – P. 169–174.The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants / The IMpact-RSV Study Group // Pediatrics. – 1998. – V. 102. – P. 531–537.The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants / The IMpact-RSV Study Group // Pediatrics. – 1998. – V. 102. – P. 531–537.Shadman, K.A. A review of palivizumab and emerging therapies for respiratory syncytial virus / K.A. Shadman, .R. Wald // Expert. Opin. Biol. Ther. – 2011. – V. 11, № 11. – P. 1455–1467.Shadman, K.A. A review of palivizumab and emerging therapies for respiratory syncytial virus / K.A. Shadman, .R. Wald // Expert. Opin. Biol. Ther. – 2011. – V. 11, № 11. – P. 1455–1467.Simões, E.A. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children / E.A. Simões [et al.] // J. Allergy. Clin. Immunol. – 2010. – V. 126. – P. 256–262.Simões, E.A. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children / E.A. Simões [et al.] // J. Allergy. Clin. Immunol. – 2010. – V. 126. – P. 256–262.Dykxhoorn, D.M. Silencing viral infection / D.M. Dykxhoorn, J. Lieberman // PLOS Medicine. – 2006. – V. 3, 7. – P. 242.Dykxhoorn, D.M. Silencing viral infection / D.M. Dykxhoorn, J. Lieberman // PLOS Medicine. – 2006. – V. 3, 7. – P. 242.Yeung, M.L. siRNA, miRNA and HIV: promises and challenges / M.L. Yeung [et al.] // Cell. Res. – 2005. – V. 15. – P. 935–946.Yeung, M.L. siRNA, miRNA and HIV: promises and challenges / M.L. Yeung [et al.] // Cell. Res. – 2005. – V. 15. – P. 935–946.Rendall, G. Progress toward the therapy of hepatitis with RNAi / G. Rendall // Hepatology. – 2005. – V. 41, № 6. – P. 1220–1222.Rendall, G. Progress toward the therapy of hepatitis with RNAi / G. Rendall // Hepatology. – 2005. – V. 41, № 6. – P. 1220–1222.Tompkins, S.M. Protection against lethal influenza virus challenge by RNA interference in vivo / S.M. Tompkins [et al.] // Proc. Natl. Acad. Sci. U.S.A. – 2004. – V. 101. – P. 8682–8686.Tompkins, S.M. Protection against lethal influenza virus challenge by RNA interference in vivo / S.M. Tompkins [et al.] // Proc. Natl. Acad. Sci. U.S.A. – 2004. – V. 101. – P. 8682–8686.Bitko, V. Inhibition of respiratory viruses by nasally administered siRNA / V. Bitko [et al.] // Nat. Med. – 2005. – V. 11. – P. 50–55.Bitko, V. Inhibition of respiratory viruses by nasally administered siRNA / V. Bitko [et al.] // Nat. Med. – 2005. – V. 11. – P. 50–55.Falsey, A.R. Respiratory syncytial virus infection in adults / A.R. Falsey // Semin. Respir. Crit. Care Med. – 2007. – V. 28. – P. 171–181.Falsey, A.R. Respiratory syncytial virus infection in adults / A.R. Falsey // Semin. Respir. Crit. Care Med. – 2007. – V. 28. – P. 171–181.Khanna, N. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature / N. Khanna [et al.] // Clin. Infect. Dis. – 2008. – V. 46. – P. 402–412.Khanna, N. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature / N. Khanna [et al.] // Clin. Infect. Dis. – 2008. – V. 46. – P. 402–412.Fire, A. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans / A. Fire [et al.] //Nature. – 1998. – V. 391. – P. 806–811.Fire, A. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans / A. Fire [et al.] //Nature. – 1998. – V. 391. – P. 806–811.Hamilton, A. Two classes of short interfering RNA in RNA silencing / A. Hamilton [et al.] // EMBO J. – 2002. – V. 21. – P. 4671–4679.Hamilton, A. Two classes of short interfering RNA in RNA silencing / A. Hamilton [et al.] // EMBO J. – 2002. – V. 21. – P. 4671–4679.Pushparaj, P.N. Short interfering RNA (siRNA) as a novel therapeutic / P.N. Pushparaj, A.J. Melendez // Clinical and Experimental Pharmacology and Physiology. – 2006. – V. 33. – P. 504–510.Pushparaj, P.N. Short interfering RNA (siRNA) as a novel therapeutic / P.N. Pushparaj, A.J. Melendez // Clinical and Experimental Pharmacology and Physiology. – 2006. – V. 33. – P. 504–510.Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, function / D.P. Bartel // Cell. – 2004. – V. 116. – P. 281–297.Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, function / D.P. Bartel // Cell. – 2004. – V. 116. – P. 281–297.Winston, W.M. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1 / W.M. Winston, C. Molodowitch , C.P. Hunter // Science. – 2002. – V. 295. – P. 2456–2459.Winston, W.M. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1 / W.M. Winston, C. Molodowitch , C.P. Hunter // Science. – 2002. – V. 295. – P. 2456–2459.Martineau, H.M. Review of the Application of RNA Interference Technology in the Pharmaceutical Industry /H.M. Martineau, I.T. Pyrah // Toxicol. Pathol. – 2007. – V. 35. – P. 327–336.Martineau, H.M. Review of the Application of RNA Interference Technology in the Pharmaceutical Industry /H.M. Martineau, I.T. Pyrah // Toxicol. Pathol. – 2007. – V. 35. – P. 327–336.Yu, Q. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication / Q. Yu, R.W. Hardy, G.W. Wertz // J. Virol. – 1995. – V. 69, № 4. – P. 2412–2419.Yu, Q. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication / Q. Yu, R.W. Hardy, G.W. Wertz // J. Virol. – 1995. – V. 69, № 4. – P. 2412–2419.Zamore, P.D. RNAi: double-stranded RNA directs the ATPdependent cleavage of mRNA at 21 to 23 nucleotide intervals / P.D. Zamore [et al.] // Cell. – 2000. – V. 101. – P. 25–33.Zamore, P.D. RNAi: double-stranded RNA directs the ATPdependent cleavage of mRNA at 21 to 23 nucleotide intervals / P.D. Zamore [et al.] // Cell. – 2000. – V. 101. – P. 25–33.Bernstein, E. Role for a bidentate ribonuclease in the initiation step of RNA interference / E. Bernstein [et al.] // Nature. – 2001. – V. 409. – P. 363–366.Bernstein, E. Role for a bidentate ribonuclease in the initiation step of RNA interference / E. Bernstein [et al.] // Nature. – 2001. – V. 409. – P. 363–366.Higuchi, Y. Strategies for in vivo delivery of siRNAs: recent progress / Y. Higuchi, S. Kawakami, M. Hashida // BioDrugs. – 2010. – V. 24. – P. 195–205.Higuchi, Y. Strategies for in vivo delivery of siRNAs: recent progress / Y. Higuchi, S. Kawakami, M. Hashida // BioDrugs. – 2010. – V. 24. – P. 195–205.Dass, C.R. Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection/ C.R. Dass // J. Mol. Med. – 2004. – V. 82. – P. 579–591.Dass, C.R. Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection/ C.R. Dass // J. Mol. Med. – 2004. – V. 82. – P. 579–591.Акимов, В.С. Подавление репродукции респираторно-синцитиального вируса методом siRNA / В.С. Акимов [и др.] // Вопр. вирусологии. – 2007. – № 2. – С. 8–12.Акимов, В.С. Подавление репродукции респираторно-синцитиального вируса методом siRNA / В.С. Акимов [и др.] // Вопр. вирусологии. – 2007. – № 2. – С. 8–12.Bitko, V. Inhibition of respiratory viruses by nasally administered siRNA / V. Bitko [et al.] // Nat. Med. – 2005. – V. 11, № 1. – P. 50–55.Bitko, V. Inhibition of respiratory viruses by nasally administered siRNA / V. Bitko [et al.] // Nat. Med. – 2005. – V. 11, № 1. – P. 50–55.Alvarez, R. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy / R. Alvarez [et al.] // Antimicrob. Agents Chemother. – 2009. – V. 53, № 9. – P. 3952–3962.Alvarez, R. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy / R. Alvarez [et al.] // Antimicrob. Agents Chemother. – 2009. – V. 53, № 9. – P. 3952–3962.Zhang, W. RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response / W. Zhang, R.A. Tripp // J. Virol. – 2008. – V. 82. – P. 12221– 12231.Zhang, W. RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response / W. Zhang, R.A. Tripp // J. Virol. – 2008. – V. 82. – P. 12221– 12231.DeVincenzo, J. A randomized, double-blind, placebocontrolled study of an RNAi-based therapy directed against respiratory syncytial virus / J. DeVincenzo [et al.] // Proc. Natl. Acad. Sci. USA. – 2010. – V. 107, № 19. – P. 8800– 8805.DeVincenzo, J. A randomized, double-blind, placebocontrolled study of an RNAi-based therapy directed against respiratory syncytial virus / J. DeVincenzo [et al.] // Proc. Natl. Acad. Sci. USA. – 2010. – V. 107, № 19. – P. 8800– 8805.Zamora, M.R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus / M.R. Zamora [et al.] // Am. J. Respir. Crit. Care Med. – 2011. – V. 183, № 4. – P. 531–538.Zamora, M.R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus / M.R. Zamora [et al.] // Am. J. Respir. Crit. Care Med. – 2011. – V. 183, № 4. – P. 531–538.

The authors declare that there are no conflicts of interest present.